January 18, 2023
Professor Robin Feldman’s article Atomistic Antitrust, coauthored with Mark A. Lemley, has been chosen for the 2023 Concurrences Antitrust Writing Awards as one of the Best Academic Articles in the subcategory of General Antitrust.
February 1, 2022
“Whenever there is a blockbuster drug, there are disputes about who owns it, who owns variations of it, who owns it for how long, and in what context,” Professor Robin Feldman told CNBC News in their story about COVID vaccines and how patent disputes…
October 21, 2021
On Oct. 19, UC Law SF Professor Robin Feldman testified before Congress in support of greater patent transparency. “To put it simply, shell games and hide-and-seek rarely make for an efficiently functioning market,” Feldman told the panel. The current patent system lacks the transparency needed to ensure…
April 6, 2021
One benefit of attending UC Law SF—with its proximity to Silicon Valley—is the opportunity to get hands-on experience working with rising entrepreneurs via the school’s Startup Legal Garage (SLG). And one benefit of being an entrepreneur in the Bay Area is the chance to get free legal assistance from law…
December 8, 2020
Key subsection titled “The Feldman Report” finds state’s insulin costs Increased by 280%. The Colorado Department of Law released a report earlier this month on the high cost of insulin and the barriers to access facing Coloradans that cited work by Professor Robin Feldman and UC Law SF’…
November 10, 2020
Prof. Robin Feldman has been honored with the 2020 Leon I. Goldberg Memorial Lecture Award by the University of Chicago’s Committee on Clinical Pharmacology and Pharmacogenomics for her work in pharmaceutical policy and law. She is the first person from outside the field of medicine to receive the award,…
October 11, 2020
The year was 2012. Few if any specialists outside of scientific labs knew what CRISPR stood for, let alone what the technology could do. But a small, select group of UC Law SF students, working with UC Law SF’ Startup Legal Garage under…
September 24, 2020
AstraZeneca, Johnson & Johnson and Gilead lead a crowded field of drug makers who excessively extend patent protections to limit the market entry of competing products in an anti-competitive practice called “evergreening,” a primary driver of high drug prices. This is one finding of many according to a public…
April 24, 2020
The UC Law SF Center for Innovation has launched a COVID-19 research project to study how information, especially regarding health care, flows during times of pandemic, and how access to health care and information varies. The research project is led by Professor Robin Feldman, Arthur J. Goldberg Distinguished Professor…
February 27, 2020
Professor Robin Feldman published an op-ed in the Washington Post in response to Health and Human Services Secretary Alex Azar’s comment that he couldn’t promise a coronavirus vaccine would be made available to Americans who couldn’t afford the medicine. The op-ed, “President Trump’s coronavirus response highlights a flawed drug…
February 11, 2020
Americans have ranked health care as one of the issues most important to them. In early 2020, the nonpartisan Law & Medicine Initiative at the UC Law SF Center for Innovation (C4i) issued a presidential advisory memo to the presidential campaigns and has updated it…
February 11, 2020
Date: February 2020* To: 2020 Presidential Campaigns From: Robin Feldman, Arthur J. Goldberg Distinguished Professor of Law and Director, Center for Innovation (C4i) Health care policy is one of the most pressing issues facing Americans today. According to a January 2020 Gallup poll, 81% of Americans cited…